ID   MRP4_HUMAN              Reviewed;        1325 AA.
AC   O15439; A9Z1Z7; B7Z3Q7; Q8IVZ4; Q8IZN6; Q8NEW8; Q9Y6J2;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Multidrug resistance-associated protein 4;
DE   AltName: Full=ATP-binding cassette sub-family C member 4;
DE   AltName: Full=MRP/cMOAT-related ABC transporter;
DE   AltName: Full=Multi-specific organic anion transporter B;
DE            Short=MOAT-B;
GN   Name=ABCC4; Synonyms=MRP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-18.
RX   PubMed=9661885;
RA   Lee K., Belinsky M.G., Bell D.W., Testa J.R., Kruh G.D.;
RT   "Isolation of MOAT-B, a widely expressed multidrug resistance-
RT   associated protein/canalicular multispecific organic anion
RT   transporter-related transporter.";
RL   Cancer Res. 58:2741-2747(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-18.
RX   PubMed=12105214; DOI=10.1074/jbc.M203262200;
RA   Adachi M., Sampath J., Lan L.B., Sun D., Hargrove P., Flatley R.,
RA   Tatum A., Edwards M.Z., Wezeman M., Matherly L., Drake R., Schuetz J.;
RT   "Expression of MRP4 confers resistance to ganciclovir and compromises
RT   bystander cell killing.";
RL   J. Biol. Chem. 277:38998-39004(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Kidney;
RA   Kato R., Ishikawa T.;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1155-1316 (ISOFORMS 1/2).
RC   TISSUE=Brain;
RX   PubMed=9270026;
RA   Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J.,
RA   Juijn J.A., Baas F., Borst P.;
RT   "Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5,
RT   homologues of the multidrug resistance-associated protein gene (MRP1),
RT   in human cancer cell lines.";
RL   Cancer Res. 57:3537-3547(1997).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-646, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-646, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-646, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   INTERACTION WITH SNX27.
RX   PubMed=22411990; DOI=10.1074/jbc.M111.337931;
RA   Hayashi H., Naoi S., Nakagawa T., Nishikawa T., Fukuda H.,
RA   Imajoh-Ohmi S., Kondo A., Kubo K., Yabuki T., Hattori A., Hirouchi M.,
RA   Sugiyama Y.;
RT   "Sorting nexin 27 interacts with multidrug resistance-associated
RT   protein 4 (MRP4) and mediates internalization of MRP4.";
RL   J. Biol. Chem. 287:15054-15065(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-646; THR-648; SER-664
RP   AND SER-668, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   VARIANTS CYS-556; ILE-776; ILE-820; PHE-854 AND VAL-866, AND
RP   CHARACTERIZATION OF VARIANTS TRP-187; ASN-304; GLU-487; CYS-556;
RP   LYS-757; ILE-776; ILE-820; PHE-854; VAL-866 AND MET-1142.
RX   PubMed=18300232; DOI=10.1002/humu.20694;
RA   Janke D., Mehralivand S., Strand D., Goedtel-Armbrust U.,
RA   Habermeier A., Gradhand U., Fischer C., Toliat M.R., Fritz P.,
RA   Zanger U.M., Schwab M., Fromm M.F., Nuernberg P., Wojnowski L.,
RA   Closs E.I., Lang T.;
RT   "6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA)
RT   transport altered by two missense mutations in the drug transporter
RT   gene ABCC4.";
RL   Hum. Mutat. 29:659-669(2008).
RN   [17]
RP   VARIANT LYS-757.
RX   PubMed=20547088; DOI=10.1016/j.legalmed.2010.04.001;
RA   Yuasa I., Umetsu K., Matsusue A., Nishimukai H., Harihara S.,
RA   Fukumori Y., Saitou N., Jin F., Chattopadhyay P.K., Henke L.,
RA   Henke J.;
RT   "A Japanese-specific allele in the GALNT11 gene.";
RL   Leg. Med. 12:208-211(2010).
CC   -!- FUNCTION: May be an organic anion pump relevant to cellular
CC       detoxification.
CC   -!- SUBUNIT: Interacts (via PDZ-binding motif) with SNX27 (via PDZ
CC       domain). {ECO:0000269|PubMed:22411990}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O15439-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15439-2; Sequence=VSP_035426;
CC       Name=3;
CC         IsoId=O15439-3; Sequence=VSP_043283, VSP_043284;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=O15439-4; Sequence=VSP_057413, VSP_043283, VSP_043284;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with particularly high
CC       levels in prostate, but is barely detectable in liver.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=O15439";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF071202; AAC27076.1; -; mRNA.
DR   EMBL; AY081219; AAL88745.1; -; mRNA.
DR   EMBL; AY207008; AAO37649.1; -; mRNA.
DR   EMBL; AF541977; AAN17334.1; -; mRNA.
DR   EMBL; AK296247; BAH12293.1; -; mRNA.
DR   EMBL; AL157818; CAC36037.2; -; Genomic_DNA.
DR   EMBL; AL139381; CAC36037.2; JOINED; Genomic_DNA.
DR   EMBL; AL356257; CAC36037.2; JOINED; Genomic_DNA.
DR   EMBL; AL139381; CAI16589.1; -; Genomic_DNA.
DR   EMBL; AL157818; CAI16589.1; JOINED; Genomic_DNA.
DR   EMBL; AL356257; CAI16589.1; JOINED; Genomic_DNA.
DR   EMBL; AL356257; CAI16722.1; -; Genomic_DNA.
DR   EMBL; AL139381; CAI16722.1; JOINED; Genomic_DNA.
DR   EMBL; AL157818; CAI16722.1; JOINED; Genomic_DNA.
DR   EMBL; AL359750; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471085; EAX08951.1; -; Genomic_DNA.
DR   EMBL; CH471085; EAX08950.1; -; Genomic_DNA.
DR   EMBL; BC041560; AAH41560.1; -; mRNA.
DR   EMBL; U83660; AAB71757.1; -; mRNA.
DR   CCDS; CCDS45061.1; -. [O15439-3]
DR   CCDS; CCDS76643.1; -. [O15439-4]
DR   CCDS; CCDS9474.1; -. [O15439-1]
DR   RefSeq; NP_001098985.1; NM_001105515.2. [O15439-3]
DR   RefSeq; NP_001288758.1; NM_001301829.1. [O15439-2]
DR   RefSeq; NP_001288759.1; NM_001301830.1. [O15439-4]
DR   RefSeq; NP_005836.2; NM_005845.4. [O15439-1]
DR   UniGene; Hs.508423; -.
DR   ProteinModelPortal; O15439; -.
DR   SMR; O15439; -.
DR   BioGrid; 115551; 17.
DR   IntAct; O15439; 6.
DR   STRING; 9606.ENSP00000366084; -.
DR   BindingDB; O15439; -.
DR   ChEMBL; CHEMBL1743128; -.
DR   DrugBank; DB00718; Adefovir Dipivoxil.
DR   DrugBank; DB00770; Alprostadil.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB00482; Celecoxib.
DR   DrugBank; DB02659; Cholic Acid.
DR   DrugBank; DB00286; Conjugated Equine Estrogens.
DR   DrugBank; DB02527; Cyclic Adenosine Monophosphate.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB00975; Dipyridamole.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00712; Flurbiprofen.
DR   DrugBank; DB00158; Folic Acid.
DR   DrugBank; DB08884; Gadoxetic acid.
DR   DrugBank; DB00143; Glutathione.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB00814; Meloxicam.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00198; Oseltamivir.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00533; Rofecoxib.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB00203; Sildenafil.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01138; Sulfinpyrazone.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   DrugBank; DB00300; Tenofovir.
DR   DrugBank; DB00352; Tioguanine.
DR   DrugBank; DB01586; Ursodeoxycholic acid.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB00495; Zidovudine.
DR   GuidetoPHARMACOLOGY; 782; -.
DR   TCDB; 3.A.1.208.7; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; O15439; -.
DR   PhosphoSitePlus; O15439; -.
DR   SwissPalm; O15439; -.
DR   BioMuta; ABCC4; -.
DR   EPD; O15439; -.
DR   MaxQB; O15439; -.
DR   PaxDb; O15439; -.
DR   PeptideAtlas; O15439; -.
DR   PRIDE; O15439; -.
DR   Ensembl; ENST00000376887; ENSP00000366084; ENSG00000125257. [O15439-1]
DR   Ensembl; ENST00000536256; ENSP00000442024; ENSG00000125257. [O15439-4]
DR   Ensembl; ENST00000629385; ENSP00000487081; ENSG00000125257. [O15439-3]
DR   GeneID; 10257; -.
DR   KEGG; hsa:10257; -.
DR   UCSC; uc001vmd.5; human. [O15439-1]
DR   UCSC; uc010tih.2; human.
DR   CTD; 10257; -.
DR   DisGeNET; 10257; -.
DR   GeneCards; ABCC4; -.
DR   HGNC; HGNC:55; ABCC4.
DR   HPA; HPA002476; -.
DR   MalaCards; ABCC4; -.
DR   MIM; 605250; gene.
DR   neXtProt; NX_O15439; -.
DR   OpenTargets; ENSG00000125257; -.
DR   PharmGKB; PA397; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00860000133687; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; O15439; -.
DR   KO; K05673; -.
DR   OMA; CAMFVII; -.
DR   OrthoDB; EOG091G00IN; -.
DR   PhylomeDB; O15439; -.
DR   TreeFam; TF105202; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   ChiTaRS; ABCC4; human.
DR   GeneWiki; ABCC4; -.
DR   GenomeRNAi; 10257; -.
DR   PRO; PR:O15439; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000125257; -.
DR   CleanEx; HS_ABCC4; -.
DR   Genevisible; O15439; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:CACAO.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0031088; C:platelet dense granule membrane; IDA:MGI.
DR   GO; GO:0016404; F:15-hydroxyprostaglandin dehydrogenase (NAD+) activity; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015662; F:ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism; TAS:Reactome.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:GO_Central.
DR   GO; GO:0043225; F:ATPase-coupled anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0060271; P:cilium assembly; IMP:MGI.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0032310; P:prostaglandin secretion; IDA:MGI.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0055085; P:transmembrane transport; IBA:GO_Central.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR030240; ABCC4.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24223:SF298; PTHR24223:SF298; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Glycoprotein;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1   1325       Multidrug resistance-associated protein
FT                                4.
FT                                /FTId=PRO_0000093362.
FT   TRANSMEM     93    113       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    136    156       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    207    227       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    228    248       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    328    348       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    351    371       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    440    460       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    710    730       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    771    791       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    836    856       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    858    878       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    954    974       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM    977    997       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TRANSMEM   1038   1058       Helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   DOMAIN       92    377       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      410    633       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN      714   1005       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1041   1274       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     445    452       ATP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND    1075   1082       ATP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   MOTIF      1322   1325       PDZ-binding.
FT   MOD_RES     646    646       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     648    648       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD    651    651       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    690    690       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    746    746       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    754    754       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    792    792       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1176   1176       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1309   1309       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     103    177       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057413.
FT   VAR_SEQ     679    725       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_035426.
FT   VAR_SEQ     846    859       TLLQVVGVVSVAVA -> RWDLAVLSWLVSNS (in
FT                                isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043283.
FT   VAR_SEQ     860   1325       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043284.
FT   VARIANT      18     18       L -> I (in dbSNP:rs11568681).
FT                                {ECO:0000269|PubMed:12105214,
FT                                ECO:0000269|PubMed:9661885}.
FT                                /FTId=VAR_046445.
FT   VARIANT      78     78       P -> A (in dbSNP:rs11568689).
FT                                /FTId=VAR_029121.
FT   VARIANT     171    171       C -> G (in dbSNP:rs4148460).
FT                                /FTId=VAR_046446.
FT   VARIANT     184    184       M -> T (in dbSNP:rs45454092).
FT                                /FTId=VAR_020241.
FT   VARIANT     187    187       G -> W (transport properties comparable
FT                                to wild-type; dbSNP:rs11568658).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_020242.
FT   VARIANT     293    293       K -> E (in dbSNP:rs11568684).
FT                                /FTId=VAR_046447.
FT   VARIANT     304    304       K -> N (transport properties comparable
FT                                to wild-type; dbSNP:rs2274407).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_022072.
FT   VARIANT     356    356       T -> M (in dbSNP:rs11568701).
FT                                /FTId=VAR_046448.
FT   VARIANT     403    403       P -> L (in dbSNP:rs11568705).
FT                                /FTId=VAR_029122.
FT   VARIANT     487    487       G -> E (transport properties comparable
FT                                to wild-type; dbSNP:rs11568668).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_029123.
FT   VARIANT     498    498       K -> E (in dbSNP:rs11568669).
FT                                /FTId=VAR_020243.
FT   VARIANT     556    556       Y -> C (40% reduced expression level
FT                                compared to wild-type; higher transport
FT                                of 9-(2-phosphonyl-methoxyethyl) adenine
FT                                than wild-type; dbSNP:rs753414892).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_045684.
FT   VARIANT     625    625       I -> M (in dbSNP:rs11568699).
FT                                /FTId=VAR_029124.
FT   VARIANT     667    667       P -> L (in dbSNP:rs11568697).
FT                                /FTId=VAR_029125.
FT   VARIANT     744    744       M -> V (in dbSNP:rs9282570).
FT                                /FTId=VAR_020244.
FT   VARIANT     757    757       E -> K (10% reduced expression level
FT                                compared to wild-type; transport
FT                                properties comparable to wild-type;
FT                                dbSNP:rs3765534).
FT                                {ECO:0000269|PubMed:18300232,
FT                                ECO:0000269|PubMed:20547088}.
FT                                /FTId=VAR_022073.
FT   VARIANT     776    776       V -> I (20% reduced expression level
FT                                compared to wild-type; significant lower
FT                                activity in 6-mercaptopurine transport
FT                                than wild-type; dbSNP:rs146708960).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_045685.
FT   VARIANT     820    820       R -> I (transport properties comparable
FT                                to wild-type; dbSNP:rs11568659).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_045686.
FT   VARIANT     854    854       V -> F (transport properties comparable
FT                                to wild-type; dbSNP:rs11568694).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_045687.
FT   VARIANT     860    860       V -> M (in dbSNP:rs45477596).
FT                                /FTId=VAR_020245.
FT   VARIANT     866    866       I -> V (transport properties comparable
FT                                to wild-type; dbSNP:rs139970608).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_045688.
FT   VARIANT     900    900       V -> L (in dbSNP:rs45504892).
FT                                /FTId=VAR_020246.
FT   VARIANT    1142   1142       T -> M (10% reduced expression level
FT                                compared to wild-type; transport
FT                                properties comparable to wild-type;
FT                                dbSNP:rs11568644).
FT                                {ECO:0000269|PubMed:18300232}.
FT                                /FTId=VAR_029126.
FT   CONFLICT    703    703       N -> S (in Ref. 2; AAL88745).
FT                                {ECO:0000305}.
FT   CONFLICT    757    757       E -> G (in Ref. 2; AAL88745).
FT                                {ECO:0000305}.
FT   CONFLICT    893    893       E -> G (in Ref. 2; AAL88745).
FT                                {ECO:0000305}.
FT   CONFLICT   1139   1139       N -> K (in Ref. 1; AAC27076).
FT                                {ECO:0000305}.
FT   CONFLICT   1302   1302       H -> D (in Ref. 8; AAB71757).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1325 AA;  149527 MW;  BF2D53136B78C0BA CRC64;
     MLPVYQEVKP NPLQDANLCS RVFFWWLNPL FKIGHKRRLE EDDMYSVLPE DRSQHLGEEL
     QGFWDKEVLR AENDAQKPSL TRAIIKCYWK SYLVLGIFTL IEESAKVIQP IFLGKIINYF
     ENYDPMDSVA LNTAYAYATV LTFCTLILAI LHHLYFYHVQ CAGMRLRVAM CHMIYRKALR
     LSNMAMGKTT TGQIVNLLSN DVNKFDQVTV FLHFLWAGPL QAIAVTALLW MEIGISCLAG
     MAVLIILLPL QSCFGKLFSS LRSKTATFTD ARIRTMNEVI TGIRIIKMYA WEKSFSNLIT
     NLRKKEISKI LRSSCLRGMN LASFFSASKI IVFVTFTTYV LLGSVITASR VFVAVTLYGA
     VRLTVTLFFP SAIERVSEAI VSIRRIQTFL LLDEISQRNR QLPSDGKKMV HVQDFTAFWD
     KASETPTLQG LSFTVRPGEL LAVVGPVGAG KSSLLSAVLG ELAPSHGLVS VHGRIAYVSQ
     QPWVFSGTLR SNILFGKKYE KERYEKVIKA CALKKDLQLL EDGDLTVIGD RGTTLSGGQK
     ARVNLARAVY QDADIYLLDD PLSAVDAEVS RHLFELCICQ ILHEKITILV THQLQYLKAA
     SQILILKDGK MVQKGTYTEF LKSGIDFGSL LKKDNEESEQ PPVPGTPTLR NRTFSESSVW
     SQQSSRPSLK DGALESQDTE NVPVTLSEEN RSEGKVGFQA YKNYFRAGAH WIVFIFLILL
     NTAAQVAYVL QDWWLSYWAN KQSMLNVTVN GGGNVTEKLD LNWYLGIYSG LTVATVLFGI
     ARSLLVFYVL VNSSQTLHNK MFESILKAPV LFFDRNPIGR ILNRFSKDIG HLDDLLPLTF
     LDFIQTLLQV VGVVSVAVAV IPWIAIPLVP LGIIFIFLRR YFLETSRDVK RLESTTRSPV
     FSHLSSSLQG LWTIRAYKAE ERCQELFDAH QDLHSEAWFL FLTTSRWFAV RLDAICAMFV
     IIVAFGSLIL AKTLDAGQVG LALSYALTLM GMFQWCVRQS AEVENMMISV ERVIEYTDLE
     KEAPWEYQKR PPPAWPHEGV IIFDNVNFMY SPGGPLVLKH LTALIKSQEK VGIVGRTGAG
     KSSLISALFR LSEPEGKIWI DKILTTEIGL HDLRKKMSII PQEPVLFTGT MRKNLDPFNE
     HTDEELWNAL QEVQLKETIE DLPGKMDTEL AESGSNFSVG QRQLVCLARA ILRKNQILII
     DEATANVDPR TDELIQKKIR EKFAHCTVLT IAHRLNTIID SDKIMVLDSG RLKEYDEPYV
     LLQNKESLFY KMVQQLGKAE AAALTETAKQ VYFKRNYPHI GHTDHMVTNT SNGQPSTLTI
     FETAL
//
